Equity
€425,779 ▼ 7.3%
BELPHARMA paid out €95,666 in dividends. That is 153% of the 2025 profit.
BELPHARMA
Lifetime
20 annual accounts with figures on one time axis, 34 filings since 1992peak €138,111 (2023)
€134,068▲ 15.3%
peak €66,700 (2023)
€62,368▲ 45.9%
peak €459,077 (2024)
€425,779▼ 7.3%
€155,534▲ 126%
peak 1.3 FTE (2010)
-not published
Board3 names since 2021
3 directors and 2 others
Documentsfilings and deeds
26-05-202666 days before the deadline
2025financial year
Gross margin from €116,277 to €134,068Result from €42,745 to €62,368Dividend €95,666Debts from €68,750 to €155,534Cash from €196,968 to €294,079
3 names are hidden.
Create a free account or sign in to see the names.
Key points
from the 2025 annual accountsTurnover
≈ €630,000 estimated
The accounts state no turnover.
Debts
€155,534 ▲ 126%
Debts rose by €86,783 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Staff
2 employees on 31-12-2025
In 2025, 1 person joined and nobody left.
Liquidity
3.06 was 6.51 in 2024
Short-term debts rose from €63,610 to €155,534.
Filings
34 annual accounts since 1992
The last five annual accounts were filed 11 to 66 days before the end of the period.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 31,368 companies had the same profile as BELPHARMA has now. Each dot stands for 79 companies, two years later.
93.5%
were still trading
5.9%
stopped another way
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for BELPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
The Checked score is hidden.
Create a free account or sign in to see the score and the bankruptcy probability.
Signals
5 signals are hidden.
Create a free account or sign in to see the signals.
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0447683110
Reappointments: (director) and (director)
“L'entreprise de pharmacie en ce compris:; La gestion d’une entreprise pharmaceutique par un ou plusieurs…” (deed in French) · General meeting of 23-05-2023 · Gazette deed
Reappointments: (director) and (director)
General meeting of 22-05-2021 · Gazette deed
First establishment
Avenue Joseph Abras 54, Namur
3 names are hidden.
Create a free account or sign in to see the names.
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BELPHARMA Namur | €581,313 | €134,068 | 73.2% | - |
| VAN EYCKEN Apotheek-Optiek Diest | €553,302 | €132,008 | 61.2% | - |
| Pharmacie de Stoumont Stoumont | €574,980 | €131,747 | 9.2% | 0 |
| APOTHEEK SINT-MAARTEN Hasselt | €550,816 | €143,837 | 78.9% | 1 |
| Apotheek Noben Sint-Truiden | €536,605 | €134,663 | 30.5% | 0 |
| Apotheek Verfaillie Tielt | €546,947 | €147,126 | 70.6% | 1.6 |
| Apotheek Ravestijn Brasschaat | €594,034 | €126,901 | 31.7% | 1.8 |
These companies have the same main activity as BELPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €537,000 and €594,000, founded between 1988 and 1995.
Official details
Source: KBO- Status
- Active since 25-06-1992Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2025
- Establishment unit
- 2.058.285.7585001 Namur, since 31-07-1992
- Financial year end
- 31 December
- Peppol
- Reachable since 12-09-2025
Annual accounts 2025
- €581,313▲ 10.1%
- Employeeson 31-12-2025
- 2▲ 100%
- Filing
- Filed on 26-05-2026, 66 days before the end of the filing period
Insights on BELPHARMA
BELPHARMA has existed since 1992. The gross margin grew from €86,925 in 2006 to €134,068 in 2025.
Solvency fell in 2025 from 87.0% to 73.2% because of the dividend.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BELPHARMA
- What is the company number of BELPHARMA?
- The company number of BELPHARMA is 0447.683.110. The VAT number is the same number with BE in front: BE 0447.683.110.
- Where is BELPHARMA based?
- The registered office is at Avenue Joseph Abras 54, 5001 Namur.Company details
- What does BELPHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of BELPHARMA?
- BELPHARMA is a public limited company (NV).
- When was BELPHARMA founded?
- BELPHARMA was founded on 25-06-1992.
- Is BELPHARMA still active?
- Yes, BELPHARMA is an active enterprise in the KBO register.
- How many employees does BELPHARMA have?
- BELPHARMA had an average of 1.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does BELPHARMA fall under?
- In its 2025 annual accounts, BELPHARMA states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of BELPHARMA?
- The turnover in financial year 2025 is ≈ €630,000. This figure is estimated from the gross margin of €134,068 and 51 comparable companies (NACE 477). It probably lies between €420,000 and €1.2m.
- Is BELPHARMA profitable?
- In financial year 2025, BELPHARMA made a profit of €62,368.
- Where can I find the annual accounts of BELPHARMA?
- BELPHARMA filed 34 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BELPHARMA due?
- BELPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.